SG Americas Securities LLC Has $140,000 Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)

SG Americas Securities LLC trimmed its stake in Denali Therapeutics Inc. (NASDAQ:DNLI) by 65.2% in the third quarter, HoldingsChannel.com reports. The firm owned 4,808 shares of the company’s stock after selling 9,000 shares during the period. SG Americas Securities LLC’s holdings in Denali Therapeutics were worth $140,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of DNLI. PNC Financial Services Group Inc. grew its holdings in Denali Therapeutics by 48.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 2,486 shares of the company’s stock worth $53,000 after acquiring an additional 807 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Denali Therapeutics by 5.5% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 26,403 shares of the company’s stock valued at $613,000 after purchasing an additional 1,372 shares in the last quarter. Swiss National Bank grew its stake in Denali Therapeutics by 0.7% during the first quarter. Swiss National Bank now owns 218,200 shares of the company’s stock worth $4,477,000 after purchasing an additional 1,500 shares during the period. GAMMA Investing LLC increased its holdings in Denali Therapeutics by 879.5% in the second quarter. GAMMA Investing LLC now owns 2,057 shares of the company’s stock worth $48,000 after purchasing an additional 1,847 shares in the last quarter. Finally, Arizona State Retirement System increased its holdings in Denali Therapeutics by 9.0% in the second quarter. Arizona State Retirement System now owns 33,114 shares of the company’s stock worth $769,000 after purchasing an additional 2,730 shares in the last quarter. 92.92% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on DNLI shares. Wedbush cut their price target on Denali Therapeutics from $30.00 to $26.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. Cantor Fitzgerald lowered shares of Denali Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, October 7th. Citigroup lifted their price target on shares of Denali Therapeutics from $26.00 to $32.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. HC Wainwright reissued a “buy” rating and set a $90.00 price objective on shares of Denali Therapeutics in a research report on Wednesday, September 4th. Finally, Bank of America raised their target price on Denali Therapeutics from $25.00 to $29.00 and gave the company a “buy” rating in a research note on Wednesday, September 4th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $38.22.

Denali Therapeutics Price Performance

Shares of NASDAQ DNLI opened at $26.15 on Friday. The company has a 50-day moving average price of $27.10 and a 200-day moving average price of $22.78. The stock has a market capitalization of $3.73 billion, a P/E ratio of -27.24 and a beta of 1.38. Denali Therapeutics Inc. has a 1 year low of $14.56 and a 1 year high of $32.13.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Thursday, August 1st. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.09. The company had revenue of $1.00 million for the quarter, compared to analyst estimates of $10.00 million. Denali Therapeutics’s revenue for the quarter was down 99.7% on a year-over-year basis. During the same quarter last year, the firm posted $1.30 EPS. As a group, equities research analysts anticipate that Denali Therapeutics Inc. will post -2.54 earnings per share for the current fiscal year.

Insider Activity at Denali Therapeutics

In related news, CEO Ryan J. Watts sold 40,000 shares of the company’s stock in a transaction on Friday, October 18th. The stock was sold at an average price of $27.69, for a total transaction of $1,107,600.00. Following the completion of the sale, the chief executive officer now owns 235,807 shares in the company, valued at approximately $6,529,495.83. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, Director Steve E. Krognes sold 30,000 shares of Denali Therapeutics stock in a transaction on Monday, September 30th. The stock was sold at an average price of $29.03, for a total transaction of $870,900.00. Following the sale, the director now directly owns 29,096 shares in the company, valued at approximately $844,656.88. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Ryan J. Watts sold 40,000 shares of the company’s stock in a transaction on Friday, October 18th. The shares were sold at an average price of $27.69, for a total value of $1,107,600.00. Following the completion of the transaction, the chief executive officer now owns 235,807 shares of the company’s stock, valued at $6,529,495.83. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.90% of the stock is owned by insiders.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.